Table 1.
Demographic and clinicopathological characteristics.
| Total | Type of surgery | p-value | ||
|---|---|---|---|---|
| n=95 | RAMIE (n=71) | MIE (n=24) | ||
| Sex | 0.5471 | |||
| male | 78 (82.1%) | 57 (80.3%) | 21 (87.5%) | |
| female | 17 (17.9%) | 14 (19.7%) | 3 (12.5%) | |
| Age, years (mean, [SD]) | 64.1 [10.3] | 63.2 [10.1] | 66.7 [10.5] | 0.1503 |
| Histopathology | 0.2502 | |||
| AEG I | 41 (43.2%) | 34 (47.9%) | 7 (29.2%) | |
| AEG II | 34 (35.8%) | 24 (33.8%) | 10 (41.7%) | |
| SCC | 20 (21.1%) | 13 (18.3%) | 7 (29.2%) | |
| cT | 0.9046 | |||
| 1 | 10 (10.5%) | 8 (11.3%) | 2 (8.3%) | |
| 2 | 14 (14.7%) | 10 (14.1%) | 4 (16.7%) | |
| 3 | 55 (57.9%) | 42 (59.1%) | 13 (54.2%) | |
| 4 | 2 (2.1%) | 1 (1.4%) | 1 (4.2%) | |
| x | 14 (14.7%) | 10 (14.1%) | 4 (16.7%) | |
| cN | 0.0945 | |||
| + | 65 (68.4%) | 45 (63.4%) | 20 (83.3%) | |
| 0 | 20 (21.1%) | 16 (22.5%) | 4 (16.7%) | |
| x | 10 (10.5%) | 10 (14.1%) | 0 (0.0%) | |
| Neoadjuvant therapy | 80 (84.2%) | 59 (83.1%) | 21 (87.5%) | 0.7535 |
| Toxicity | 39 (48.8%) | 25 (42.4%) | 14 (66.7%) | 0.0759 |
| Severe Toxicity | 16 (42.1%) | 6 (25%) | 10 (71.4%) | 0.0077 |
| Pre-existing conditions | ||||
| Cardiovascular | 55 (57.9%) | 40 (56.3%) | 15 (62.5%) | 0.6401 |
| Pulmonary | 15 (15.8%) | 11 (15.5%) | 4 (16.7%) | 1.0000 |
| Diabetes | 10 (10.5%) | 7 (9.9%) | 3 (12.5%) | 0.7094 |
| Other malignancies | 14 (14.7%) | 11 (15.5%) | 3 (12.5%) | 0.3018 |
|
Nutritional status
Albumin, g/dl (median, [IQR]) |
37.4 [34.7-39.8] |
37.6 [35.3-39.9] |
37.0 [32.6-39.5] |
0.1956 |
| Cholesterol, mg/dl (mean, [SD]) | 209.7 [49.9] | 211.3 [51.7] | 204.4 [44.2] | 0.8242 |
| Preoperative BMI, kg/m2 (median, [IQR]) | 25.2 [22.6-27.9] | 25.3 [22.8-27.9] | 24.7 [22.0-27.6] | 0. 6622 |
RAMIE, robot-assisted minimally invasive esophagectomy; MIE, minimally invasive esophagectomy; AEG, adenocarcinoma of the esophagogastric junction; SCC, squamous cell carcinoma; SD, standard deviation; IQR, interquartile range; p<0.05 are marked in bold.